Value of combined detection of fecal genes SDC2 and BMP3 methylation in screening for colorectal cancer
PAN Hui1 HUANG Yanying2 WANG Guoxin3 WU Hui1 SONG Huidong4 HUANG Yingfeng1
1.Department of General Surgery, Guangzhou Twelfth People′s Hospital Affiliated to Guangzhou Medical University, Guangdong Province, Guangzhou 510620, China;
2.Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangdong Province, Guangzhou 510060, China;
3.Department of Central Laboratory, Guangzhou Twelfth People′s Hospital Affiliated to Guangzhou Medical University, Guangdong Province, Guangzhou 510620, China;
4.Department of Gastroenterology, Guangzhou Twelfth People′s Hospital Affiliated to Guangzhou Medical University, Guangdong Province, Guangzhou 510620, China
Abstract：Objective To investigate the diagnostic performance of stool gene syndecan-2(SDC2) and bone morphogenetic protein 3(BMP3) methylation in colorectal cancer. Methods Fecal samples were collected from 64 patients admitted to Guangzhou Twelfth People′s Hospital Affiliated to Guangzhou Medical University and the Cancer Hospital Affiliated to Sun Yat-sen University from May to September 2019, of which 29 cases were in the colorectal cancer group, 9 cases were in the adenoma group, and 26 cases were in the control group (patients without colon cancer, adenoma). Fecal DNA was extracted, and methylation-specific PCR was used to detect the methylation of fecal genes SDC2 and BMP3 of patients in three groups. The sensitivity and specificity of colorectal cancer and adenoma were compared. Results The combined detection of stool gene SDC2 and BMP3 were more sensitive than BMP3 in the diagnosis of colorectal cancer, and the differences were statistically significant (P ＜ 0.05). The comparison of AUC values of SDC2, BMP3, and combined detection in colorectal cancer were highly statistically significant (P ＜ 0.01). The AUC value of the combined test was higher than that of the BMP3 test, and the difference was statistically significant (Z = 2.361, P ＜ 0.05). The detection rate of BMP3 and combined detection on different distribution sites were statistically significant (P ＜ 0.05). Conclusion The diagnostic performance of stool gene SDC2 and BMP3 detection in colorectal cancer is better than that of BMP3 detection, but there is no significant improvement compared with SDC2 detection.
潘辉1 黄琰璎2 王国新3 吴辉1 宋慧东4 黄颖烽1. 粪便基因SDC2和BMP3甲基化联合检测在结直肠癌筛查中的价值[J]. 中国医药导报, 2020, 17(11): 15-19.
PAN Hui1 HUANG Yanying2 WANG Guoxin3 WU Hui1 SONG Huidong4 HUANG Yingfeng1. Value of combined detection of fecal genes SDC2 and BMP3 methylation in screening for colorectal cancer. 中国医药导报, 2020, 17(11): 15-19.
[1] 郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019，41（1）：19-28.
[2] Chen H，Li N，Ren J，et al. Participation and yield of a population-based colorectal cancer screening programme in China [J]. Gut，2019，68（8）：1450-1457.
[3] Imperiale TF，Ransohoff DF，Itzkowitz SH，et al. Multitarget stool DNA testing for colorectal-cancer screening [J]. N Engl J Med，2014，370（14）：1287-1297.
[4] Bosch LJW，Melotte V，Mongera S，et al. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population [J]. Am J Gastroenterol，2019， 114（12）：1909-1918.
[5] Mu J，Huang Y，Cai S，et al. Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia [J]. Clin Chim Acta，2020，501：42-47.
[6] Oh T，Kim N，Moon Y，et al. Genome-wide identification and validation of a novel methylation biomarker，SDC2，for blood-based detection of colorectal cancer [J]. J Mol Diagn，2013，15（4）：498-507.
[7] Niu F，Wen J，Fu X，et al. Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia [J]. Cancer Epidemiol Biomarkers Prev，2017，26（9）：1411-1419.
[8] Han YD，Oh TJ，Chung TH，et al. Early detection of colorectal cancer based on presence of methylated syndecan-2（SDC2）in stool DNA [J]. Clin Epigenetics，2019，11（1）：51.
[9] Wen J，Liu X，Qi Y，et al. BMP3 suppresses colon tumorigenesis via ActRⅡB/SMAD2-dependent and TAK1/JNK signaling pathways [J]. J Exp Clin Cancer Res，2019，38（1）：428.
[10] Loh K，Chia JA，Greco S，et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development [J]. Genes Chromosomes Cancer，2008，47（6）：449-460.
[11] 蔡克银，徐梅华，王晓.粪便DNA中联合SFRP1及SEPT9基因甲基化检测对老年性结直肠癌早期诊断的临床研究[J].临床肿瘤学杂志，2018，23（1）：25-29.
[12] Zhang H，Zhu YQ，Wu YQ，et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer [J]. World J Gastroenterol，2014，20（20）：6329-6335.
[13] 柏愚，刘晶，康倩，等.联合检测SDC2和SFRP2甲基化在结直肠癌筛查中的价值[J].中华消化内镜杂志，2019， 36（6）：427-432.
[14] 肖著军，王新颖，李丙生，等.联合检测vimentin和SFRP2甲基化在大肠癌筛查中的应用评价[J].现代消化及介入诊疗，2014，19（1）：13-16.
[15] Amin MB，Edge S，Greene F，et al. AJCC Cancer Staging Manual. 8th ed [M]. New York：Springer，2017.
[16] Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[17] Park SK，Baek HL，Yu J，et al. Is methylation analysis of SFRP2，TFPI2，NDRG4，and BMP3 promoters suitable for colorectal cancer screening in the Korean population? [J]. Intest Res，2017，15（4）：495-501.
[18] Chen J，Sun H，Tang W，et al. DNA methylation biomarkers in stool for early screening of colorectal cancer [J]. J Cancer，2019，10（21）：5264-5271.
[19] Sun M，Liu J，Hu H，et al. A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population [J]. J Cancer Res Clin Oncol，2019，145（10）：2423-2432.
[20] US Preventive Services Task Force，Bibbins-Domingo K，Grossman DC，et al. Screening for Colorectal Cancer： US Preventive Services Task Force Recommendation Statement [J]. JAMA，2016，315（23）：2564-2575.
2020, Vol. 17 
京公网安备 11010502046598号